Recent Advances in the Management of Chronic Hepatitis B

How to Cite:Kim S R, Yang J, Kudo M, Hino O. Recent Advances in the Management of Chronic Hepatitis B.Hepat Mon.2011;11(8):601-611.https://doi.org/10.5812/kowsar.1735143X.657.

Abstract

There are seven approved treatments for adults with chronic hepatitis B virus infection in the United States and European countries: interferon-α, pegylated interferon-α, lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate. At present, two new analogues, entecavir and tenofovir are recommended as the first line therapy by the guidelines of European Association for the Study of the Liver and American Association Study for the Liver Diseases. On the other hand, regarding interferon therapy, use of pegylated interferon-α is recommended as the first line therapy instead of standard interferon-α by both guidelines. Therefore, the main scientific interests and unmet medical needs for treatment of chronic hepatitis B have been narrowed down to long-term efficacy and safety of the two said analogues-entecavir and tenofovir-and combination therapy of pegylated interferon-α with the two analogues. To put it concretely, further studies are needed to assess (1) the long-term efficacy and safety and resistance to entecavir and tenofovir; (2) the efficacy of different durations (24 weeks to 2 years) and lower doses of pegylated interferon-α; (3) the role of combination therapy with two analogues to reduce resistance; and (4) the efficacy and safety of the two analogues with decompensated cirrhosis. Herein, we review the recent available data and results.

Keywords: Hepatitis B virus; Interferon alpha; Nucleotide analogues; Entecavir; Tenofovir

Implication for health policy/practice/research/medical education:
Several therapeutic modalities exist for the treatment of chronic hepatitis B. Based on recent available data, this review endeavors to present the long-term efficacy and safety of these modalities especially for entecavir and tenofovir as well as pegylated interferon-α.
Please cite this paper as:
Kim SR, Yang J, Kudo M, Hino O. Recent Advances in the Management of Chronic Hepatitis B. Hepat Mon. 2011;11(8):601-11. [DOI: 10.5812/kowsar.1735143X.657]

Keywords

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 3 days ago
Scopus by Title: 8
Last Update: 3 days ago
Scopus by Title (Ref): 17
Last Update: 3 days ago
CrossRef: 1
Last Update: 6 days ago

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Soo Ryang Kim:[PubMed][Scholar]
Jisin Yang:[PubMed][Scholar]
Masatoshi Kudo:[PubMed][Scholar]
Okio Hino:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

Recent Advances in the Management of Chronic Hepatitis B

Abstract

Full Text

Crossmark

Checking

Last Update: 3 days ago

Last Update: 3 days ago

Last Update: 3 days ago

Last Update: 6 days ago